Pharming Group N.V. (PHAR) Balance Sheet

NASDAQ: PHARAssets, liabilities, debt and equity over 10 years.

PHAR balance sheet, 2025

December 31, 2025 · U.S. dollars

$499.8M assets = $222.8M liabilities + $277.0M equity

What it owns$499.8MCash & ST investments: $179.8M (36.0%)Cash & ST investments$179.8M · 36%Receivables: $54.7M (10.9%)Receivables $54.7MInventory: $64.9M (13.0%)Inventory $64.9MOther current: $1,001 (0.0%)PP&E: $24.0M (4.8%)Goodwill & intangibles: $267.7M (53.6%)Goodwill & intangibles$267.7M · 54%LT investments: $8.6M (1.7%)=How it is financed$499.8MCurrent liabilities: $115.8M (23.2%)Current liabilities$115.8M · 23%Long-term debt: $92.7M (18.6%)Long-term debt$92.7M · 19%Other LT liabilities: $14.4M (2.9%)Shareholders’ equity: $277.0M (55.4%)Shareholders’ equity$277.0M · 55%

Both columns are drawn to the same scale: what PHAR owns equals what it owes plus shareholders’ equity. Hover a block for its value.

PHAR financial health

Current ratio2.59
Comfortable · current assets cover current liabilities 2.59×
Debt / equity0.42
Low leverage · $0.42 of debt for each $1 of equity
Equity / assets55.4%
Equity-funded · of assets funded by shareholders
Cash / debt155.3%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles53.6%
Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

PHAR balance sheet trends, 2016–2025

Pharming Group N.V. balance sheet trends
MetricTrendThenLatestChange
Total assets$133.3M2016$499.8M2025+15.8%/yr
Total liabilities$104.5M2016$222.8M2025+8.8%/yr
Shareholders’ equity$27.5M2016$277.0M2025+29.3%/yr
Cash & short-term investments$33.5M2016$179.8M2025+20.5%/yr
Total debt$67.4M2016$115.8M2025+6.2%/yr
Net cash (debt)−$33.9M2016$64.0M2025+$97.9M
Working capital$11.4M2016$183.6M2025+$172.2M
Book value per share$0.532016$3.882025+24.8%/yr
Current ratio1.2120162.592025+1.38
Debt / equity2.4520160.422025−2.04
Shares outstanding51.9M201671.3M2025+3.6%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

PHAR assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

PHAR liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

PHAR debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

PHAR balance sheet

Pharming Group N.V. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$179.8M$173.9M$213.4M$207.3M$217.6M$167.9M$74.3M$80.3M$70.4M$33.5M
Cash & equivalents$146.0M$56.9M$61.7M$207.3M$217.6M$167.9M$74.3M$80.3M$70.4M$33.5M
Short-term investments$33.8M$117.0M$151.7M$0——−$661,908———
Receivables$54.7M$52.0M$42.6M$25.3M$31.3M$19.2M$28.9M$15.3M$8.9M$6.3M
Inventory$64.9M$57.7M$56.8M$42.3M$31.0M$17.3M$16.2M$17.3M$22.0M$18.9M
Other current assets$1,001$4.8M$3.5M$2.5M$3.0M$11.0M$0$2.5M$4.6M$6.7M
Total current assets$299.4M$288.3M$316.3M$277.5M$282.8M$215.5M$119.4M$115.4M$105.9M$65.4M
Property, plant & equipment (net)$24.0M$24.1M$33.5M$39.1M$37.6M$17.7M$16.3M$9.6M$9.9M$6.4M
Goodwill & intangible assets$267.7M$63.2M$71.3M$75.1M$95.0M$72.6M$79.4M$60.0M$67.9M$59.6M
Long-term investments$8.6M$4.2M$10.4M$9.7M$8.8M$5.8M$5.5M$0$0$0
Other non-current assets$0$34.3M$31.4M$24.3M$26.3M$31.0M$35.3M$29.5M$15.7M$2.0M
Total assets$499.8M$414.2M$462.9M$425.8M$450.4M$342.5M$255.9M$214.5M$199.4M$133.3M
Liabilities
Accounts payable$105.9M$10.5M$16.0M$8.8M$8.6M$11.0M$40.6M$7.6M$11.3M$5.9M
Short-term debt$8.7M$7.4M$5.4M$5.2M$4.9M$3.3M$53.3M$40.6M$22.7M$26.4M
Deferred revenue———−$56,233−$44,352$34.3M$34.6M$915,122$964,560$991,754
Total current liabilities$115.8M$76.4M$78.0M$59.7M$53.0M$62.9M$114.3M$82.6M$70.2M$54.0M
Long-term debt$92.7M$78.2M$136.6M$131.6M$122.6M$121.9M$0$37.3M$58.7M$0
Lease obligations$17.7M$29.9M$33.1M$33.3M$18.4M$8.3M$6.3M$427,000$653,000—
Other long-term liabilities$14.4M$30.7M$29.5M$29.8M$56.1M$7.6M$24.3M$32.9M$47.9M$47.9M
Total liabilities$222.8M$185.3M$244.1M$221.2M$231.7M$192.4M$138.5M$152.7M$176.8M$104.5M
Shareholders' equity
Common stock & paid-in capital$8.0M$8.0M$7.7M$7.5M$8.4M$6.0M$7.2M$6.2M$5.8M$4.6M
Retained earnings (deficit)−$272.9M−$285.3M−$265.3M−$256.4M−$309.7M−$221.8M−$340.7M−$332.0M−$353.5M−$279.0M
Accumulated other comprehensive income—−$216,417−$2.1M−$8.7M$3.9M$24.6M$8.9M$1.9M−$1.1M$63,102
Minority interest$0$0————————
Total shareholders' equity$277.0M$228.9M$218.8M$204.6M$218.7M$150.2M$117.4M$61.8M$16.1M$27.5M
Key figures
Total debt$115.8M$116.3M$171.5M$166.7M$183.4M$132.6M$58.2M$83.4M$82.2M$67.4M
Net cash (debt)$64.0M$57.6M$41.9M$40.6M$34.2M$35.4M$16.1M−$3.1M−$11.8M−$33.9M
Working capital$183.6M$211.9M$238.4M$217.8M$229.8M$152.6M$5.2M$32.8M$35.7M$11.4M
Tangible book value$9.3M$165.7M$147.5M$129.5M$123.8M$77.6M$38.0M$1.8M−$51.8M−$32.1M
Book value per share$3.88$3.32$3.33$2.43$2.50$1.85$1.39$0.76$0.26$0.53
Shares outstanding71.3M68.9M65.7M84.3M87.6M81.0M84.2M81.7M62.6M51.9M
Current ratio2.593.774.064.655.333.431.051.401.511.21
Quick ratio2.032.953.283.904.692.980.901.161.130.74
Debt / equity0.420.510.780.810.840.880.501.355.102.45
Equity / assets55.4%55.3%47.3%48.1%48.6%43.8%45.9%28.8%8.1%20.6%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 2, 2026); data from EODHD.

PHAR financial position

At the end of fiscal 2025 (December 31, 2025), Pharming had total assets of $499.8 million (up 20.7% from a year earlier), total liabilities of $222.8 million and shareholders' equity of $277.0 million. It held $179.8 million in cash and short-term investments against $115.8 million of debt, a net cash position of $64.0 million. Its current ratio was 2.59. In the latest quarter (ended June 30, 2026) total assets were $468.0 million and equity $270.5 million.

Related: PHAR income statement, PHAR cash flow statement, PHAR key metrics. See the PHAR stock overview for the latest quote and news.

PHAR balance sheet FAQ

What are Pharming's total assets?

Pharming reported total assets of $499.8 million at the end of fiscal 2025 (December 31, 2025), compared with $414.2 million a year earlier.

How much debt does Pharming have?

Pharming had $115.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.42.

How much cash does Pharming have?

Pharming held $179.8 million in cash and short-term investments at the end of fiscal 2025; with $115.8 million of debt that is net cash of $64.0 million.

What is Pharming's book value?

Pharming's shareholders' equity (book value) was $277.0 million at the end of fiscal 2025, or $3.88 per share.

What is Pharming's current ratio?

Pharming had current assets of $299.4 million and current liabilities of $115.8 million, a current ratio of 2.59 (it can cover its short-term obligations).

How much goodwill does Pharming have?

Pharming carried $267.7 million of goodwill and intangible assets, 53.6% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet